Cedar Brook Financial Partners’s AbbVie ABBV Stock Holding History

Cedar Brook Financial Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,051	Closed	-$738K	–	30
2024 Q1	$738K	Buy	4,051 +613	+18%	+$106K	0.15%	160
2023 Q4	$563K	Buy	3,438 +119	+4%	+$17.3K	0.13%	177
2023 Q3	$495K	Sell	3,319 -339	-9%	-$49.8K	0.13%	175
2023 Q2	$493K	Sell	3,658 -63	-2%	-$9.24K	0.12%	184
2023 Q1	$593K	Buy	3,721 +402	+12%	+$61.5K	0.15%	154
2022 Q4	$536K	Sell	3,319 -72	-2%	-$11K	0.15%	161
2022 Q3	$455K	Buy	3,391 +455	+15%	+$65.3K	0.15%	176
2022 Q2	$450K	Buy	2,936 +129	+5%	+$19.7K	0.14%	177
2022 Q1	$455K	Buy	2,807 +638	+29%	+$92.7K	0.12%	199
2021 Q4	$294K	Buy	+2,169	New	+$256K	0.08%	284
2021 Q3	–	Sell	-2,043	Closed	-$230K	–	347
2021 Q2	$230K	Buy	+2,043	New	+$230K	0.07%	330
2021 Q1	–	Sell	-1,997	Closed	-$214K	–	319
2020 Q4	$214K	Buy	+1,997	New	+$192K	0.08%	290
2020 Q3	–	Sell	-2,172	Closed	-$213K	–	294
2020 Q2	$213K	Buy	+2,172	New	+$191K	0.09%	245

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Cedar Brook Financial Partners's ABBV Position: Q2 2024 in Review

Cedar Brook Financial Partners sold out of AbbVie (ABBV) in Q2 2024, closing a stake of 4,051 shares — an estimated $738K sold.

Cedar Brook Financial Partners first reported a position in ABBV in Q2 2020 and held it in 13 quarters. The position peaked at $738K in Q1 2024. 3,364 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.

Cedar Brook Financial Partners reported no remaining AbbVie position as of Q2 2024 after selling out during the quarter.
Cedar Brook Financial Partners sold 4,051 AbbVie shares in Q2 2024, an estimated $738K.
Cedar Brook Financial Partners first reported a position in AbbVie in Q2 2020 and held it in 13 quarters.
Cedar Brook Financial Partners's AbbVie position peaked at $738K in Q1 2024.
3,364 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.

Based on Cedar Brook Financial Partners's 13F filing for Q2 2024, filed 15 Jul 2024.